scholarly journals Acute Effects of Pimobendan on Cardiac Function in Dogs With Tachycardia Induced Dilated Cardiomyopathy: A Randomized, Placebo-Controlled, Crossover Study

2021 ◽  
Vol 8 ◽  
Author(s):  
Kaitlin Abbott-Johnson ◽  
Kursten V. Pierce ◽  
Steve Roof ◽  
Carlos L. del Rio ◽  
Robert Hamlin

Background: Pimobendan provides a significant survival benefit in dogs with cardiac disease, including degenerative mitral valve disease and dilated cardiomyopathy (DCM). Its positive inotropic effect is well-known, however, it has complex effects and the mechanisms behind the survival benefit are not fully characterized. Secondary hemodynamic effects may decrease mitral regurgitation (MR) in DCM, and the benefits of pimobendan may extend to improved cardiac relaxation and improved atrial function.Hypothesis/Objectives: Our objective was to investigate the acute cardiac effects of pimobendan in dogs with a DCM phenotype. We hypothesized that pimobendan would increase left atrial (LA) contractility, reduce mitral regurgitation, improve diastolic function, and lower circulating NT-ProBNP levels.Animals: Seven purpose-bred Beagles were studied from a research colony with tachycardia induced DCM phenotype.Methods: The effects of pimobendan were studied under a placebo-controlled single-blinded cross-over design. In short, dogs underwent baseline and 3 h post-dose examinations 7 days apart with echocardiography and a blood draw. Dogs were randomized to receive oral placebo or 0.25 mg/kg pimobendan after their baseline exam. Investigators were blinded to treatments until all measurements were compiled.Results: When treated with pimobendan, the dogs had significant increases in systolic function and decreases in MR, compared to when treated with placebo.There were no detectable differences in left atrial measures, including LA size, LA emptying fraction, LA functional index or mitral A wave velocity. Heart rate decreased significantly with pimobendan compared to placebo. There was also a decrease in isovolumetric relaxation time normalized to heart rate. NT-proBNP levels had a high degree of variability.Conclusions: Improved mitral regurgitation severity and improved lusitropic function may contribute to the reported survival benefit for dogs with cardiac disease administered pimobendan. Pimobendan did not overtly improve LA function as assessed by echocardiography, and NT-proBNP was not significantly changed with a single dose of this medication. Further studies are needed to better characterize LA effects with other imaging modalities, to better quantify the total improvement of MR severity, and to assess chronic use of pimobendan on diastolic function in DCM.

2020 ◽  
pp. 1-3
Author(s):  
Aslak Widerøe Kristoffersen ◽  
Per Kristian Knudsen ◽  
Thomas Møller

Abstract A four- and a half-month-old girl with severe dilated cardiomyopathy due to neonatal enterovirus myocarditis, treated with diuretics and milrinone for the past 4 months, was infected with SARS-CoV-2. The disease course was characterised by high fever and gastrointestinal symptoms. Cardiac function, as measured by echocardiography, remained stable. The treatment focused on maintaining a normal heart rate and a stable fluid balance. In children with severe underlying cardiac disease, even a mild SARS-CoV-2 infection can require close monitoring and compound treatment.


1994 ◽  
Vol 47 (2) ◽  
pp. 139-143 ◽  
Author(s):  
Athanasios Trikas ◽  
Filippos Triposkiadis ◽  
Christos Pitsavos ◽  
Konstantinos Tentolouris ◽  
Michael Kyriakidis ◽  
...  

1992 ◽  
Vol 70 (7) ◽  
pp. 825-827 ◽  
Author(s):  
Filippos Triposkiadis ◽  
Athanasios Trikas ◽  
Christos Pitsavos ◽  
Petros Papadopoulos ◽  
Pavlos Toutouzas

2019 ◽  
Vol 7 (27) ◽  
pp. 64-66 ◽  
Author(s):  
Phumpattra Chariyawong ◽  
Angela Rao ◽  
Deepa Panikkath ◽  
Ragesh Panikkath

Hyperthyroidism is a common endocrine disorder with a prevalence of 1.3% in the generalpopulation, affecting more women than men. Prolonged hyperthyroidism without appropriatemanagement may lead to high output cardiac failure characterized by increases in heart rate,cardiac contractility, and cardiac output and by reductions in peripheral systemic vascularresistance. Dilated cardiomyopathy with impaired systolic function is rare and occurs in lessthan 1% of patients with thyrotoxicosis. The exact mechanism of hyperthyroidism-induceddilated cardiomyopathy is not well established. The combination of direct toxic effects of excessthyroid hormone along with prolonged tachycardia, arrhythmia, and a hyperdynamic state couldbe contributing factors. We present a case of a young woman with prolonged sinus tachycardiadue to a long history of medication non-compliance who developed dilated cardiomyopathywith low output heart failure. Early detection and management of hyperthyroidism are crucialto restore cardiac function.


1998 ◽  
Vol 31 ◽  
pp. 149
Author(s):  
F. Triposkiadis ◽  
I. Moyssakis ◽  
N. Dalianis ◽  
N. Strateges ◽  
A. Athanassiou ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document